Advertisement

Prevention and Treatment Regimens for Non-viral Infections in the Lung Transplant Recipient

  • Martin R. Zamora
Chapter

Abstract

Lung transplantation has become an accepted treatment for patients with end-stage pulmonary parenchymal and vascular disease. Despite more than two decades of improvements in surgical technique and immunosuppressive agents, long-term survival of the lung transplant recipient continues to lag behind other solid organ transplants. Infection remains the leading cause of morbidity and mortality at all time points following lung transplantation. Challenges in managing infections in the lung transplant recipient include (1) difficulty in the recognition of and early diagnosis of infection as infectious signs and symptoms may be masked by immunosuppressive agents; (2) acute cellular rejection that may present as a febrile illness with chest radiographic changes in the lung transplant recipient; (3) significant drug-drug interactions between anti-infectious agents and immunosuppressive medications and their toxic side effects; (4) a broad array of pathogens causing clinical disease; and (5) the rapid progression of infections. Invasive diagnostic tests are typically required to make a timely diagnosis which is essential to optimize treatment and limit adverse side effects and immunosuppressive drug interactions. This chapter will review the prevention, diagnosis, and treatment of common non-viral infections in lung transplant recipients.

Keywords

Lung transplant Infectious complications Pseudomonas Staphylococcus aureus Candida Aspergillus 

References

  1. 1.
    Len O, Gavalda J, Blanes M, Montejo M, San Juan R, Moreno A, et al. Donor infection and transmission to the recipient of a solid allograft. Am J Transplant. 2008;8:2420–5.CrossRefPubMedGoogle Scholar
  2. 2.
    Fishman JA. Infection in solid organ transplant recipients. N Engl J Med. 2007;357:2601–14.CrossRefPubMedGoogle Scholar
  3. 3.
    Weigt SS, Elashoff RM, Huang C, Ardehali A, Gregson AL, Kubak B, et al. Aspergillus colonization of the lung allograft is a risk factor for bronchiolitis obliterans syndrome. Am J Transplant. 2009;9:1903–11.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Lease ED, Zaas DW. Complex bacterial infections pre- and post-transplant. Semin Respir Crit Care Med. 2010;31:234–42.CrossRefPubMedGoogle Scholar
  5. 5.
    Hsu JL, Khan MA, Sobel RA, Jiang X, Clemons KV, Nguyen TT, et al. Aspergillus fumigatus invasion increases with progressive airway ischemia. PLoS One. 2013;14:e77136.CrossRefGoogle Scholar
  6. 6.
    Gunderson CC, Gupta MR, Lopez F, Lombard GA, LaPlace SG, Taylor DE, et al. Clostridium difficile colitis in lung transplantation. Transpl Infect Dis. 2008;10:245–51.CrossRefPubMedGoogle Scholar
  7. 7.
    Singh N. Fungal infections in the recipients of solid organ transplantation. Infect Dis Clin N Am. 2003;17:113–34.CrossRefGoogle Scholar
  8. 8.
    Avery RK. Infections after lung transplantation. Semin Respir Crit Care Med. 2006;27:544–51.CrossRefPubMedGoogle Scholar
  9. 9.
    Lynch JP, Sayah DM, Belperio JA, Weigt SS. Lung transplantation for cystic fibrosis: results, indications, complications and controversies. Semin Respir Crit Care Med. 2015;36:299–320.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Shoham S, Shah PD. Impact of multidrug-resistant organisms on patients considered for lung transplantation. Infect Dis Clin N Am. 2013;27:343–58.CrossRefGoogle Scholar
  11. 11.
    Dobbin C, Maley M, Harkness J, Benn R, Malouf M, Glanville A, et al. The impact of pan-resistant bacterial pathogens on survival after lung transplantation in cystic fibrosis: results from a single large referral center. J Hosp Infect. 2004;56:277–82.CrossRefPubMedGoogle Scholar
  12. 12.
    Hadjiliadis D, Steele MP, Chaparro C, Singer LG, Waddell TK, Hutcheon MA, et al. Survival of lung transplant patients with cystic fibrosis harboring panresistant bacteria other than Burkholderia cepacia, compared with patients harboring sensitive bacteria. J Heart Lung Transplant. 2007;26(8):834.CrossRefPubMedGoogle Scholar
  13. 13.
    Nunley DR, Bauldoff GS, Mangino JE, Pope-Harman AL. Mortality associated with Acinetobacter baumanii infections experienced by lung transplant recipients. Lung. 2010;188(5):381.CrossRefPubMedGoogle Scholar
  14. 14.
    Denton M, Kerr KG. Microbiological and clinical aspects of infection associated with Stenotrophomonas maltophilia. Clin Microbiol Rev. 1998;11:57–80.PubMedPubMedCentralGoogle Scholar
  15. 15.
    Van Delden C, Blumberg EA. Multidrug resistant gram-negative bacteria in solid organ transplant recipients. Am J Transplant. 2009;9(Suppl 4):S27–34.CrossRefPubMedGoogle Scholar
  16. 16.
    Peleg AY, Hooper DC. Hospital-acquired infections due to gram negative bacteria. N Engl J Med. 2010;362:1804–13.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Boussaud V, Guillerrmain R, Grenet D, Coley N, Souilamas R, Bonnette P, et al. Clinical outcome following lung transplantation in patients with cystic fibrosis colonized with Burkholderia cepacia complex: results from two French centres. Thorax. 2008;63:732–7.CrossRefPubMedGoogle Scholar
  18. 18.
    Alexander BD, Petzold EW, Reller LB, Palmer SM, Davis RD, Woods CW, et al. Survival after lung transplantation of cystic fibrosis patients infected with Burkholderia cepacia complex. Am J Transplant. 2008;8:1025–30.CrossRefPubMedGoogle Scholar
  19. 19.
    Murray S, Charbeneau J, Marshall BC, LiPuma JJ. Impact of Burkholderia infection on lung transplantation in cystic fibrosis. Am J Respir Crit Care Med. 2008;178:363–71.CrossRefPubMedGoogle Scholar
  20. 20.
    Hafkin J, Blumberg E. Infections in lung transplantation: new insights. Curr Opin Organ Transplant. 2009;14:483–7.CrossRefPubMedGoogle Scholar
  21. 21.
    Weill D, Benden C, Corris PA, Dark JH, Davis RD, Keshavjee S, et al. A consensus document for the selection of lung transplant candidates: 2014—an update from the pulmonary transplantation council of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant. 2015;34:1–15.CrossRefPubMedGoogle Scholar
  22. 22.
    Chaparro C, Maurer J, Gutierrez C, Krajden M, Chan C, Winton T, et al. Infection with Burkholderia cepacia in cystic fibrosis: outcome following lung transplantation. Am J Respir Crit Care Med. 2001;163:43–8.CrossRefPubMedGoogle Scholar
  23. 23.
    Clark NM. Nocardia in solid organ transplant recipients. Am J Transplant. 2009;9(Suppl 4):S70–7.CrossRefPubMedGoogle Scholar
  24. 24.
    Tripodi MF, Adinolfi LE, Andreana A, Sarnataro G, Durante Mangoni E, Gambardella M, et al. Treatment of pulmonary nocardiosis in heart-transplant patients: importance of susceptibility studies. Clin Transpl. 2001;15:415–20.CrossRefGoogle Scholar
  25. 25.
    Minero MV, Marin M, Cercenado E, Rabadan PM, Bouza E, Munoz P. Nocardiosis at the turn of the century. Medicine. 2009;88:250–61.CrossRefPubMedGoogle Scholar
  26. 26.
    Lopez FA, Johnson F, Novosad DM, Beaman BL, Holodniy M. Successful management of disseminated Nocardia transvalensis infection in a heart transplant recipient after development of sulfonamide resistance: case report and review. J Heart Lung Transplant. 2003;22:492–7.CrossRefPubMedGoogle Scholar
  27. 27.
    Wallace RJ Jr, Septimus EJ, Williams TW Jr, Conklin RH, Satterwhite TK, Bushby MB, et al. Use of trimethoprim-sulfamethoxazole for treatment of infections due to nocardia. Rev Infect Dis. 1982;4:315–25.CrossRefPubMedGoogle Scholar
  28. 28.
    Weber L, Yium J, Hawkins S. Intracranial Nocardia dissemination during minocycline therapy. Transpl Infect Dis. 2002;4:108–12.CrossRefPubMedGoogle Scholar
  29. 29.
    Lerner PI. Nocardiosis. Clin Infect Dis. 1996;22:891–903.CrossRefPubMedGoogle Scholar
  30. 30.
    Peleg AY, Husain S, Qureshi ZA, Silveira FP, Sarumi M, Shutt KA, et al. Risk factors, clinical characteristics, and outcomes of nocardia infection in organ transplant recipients: a matched case-control study. Clin Infect Dis. 2007;44:1307–14.CrossRefPubMedGoogle Scholar
  31. 31.
    Sole A, Salavert M. Fungal infections after lung transplantation. Transplant Rev. 2008;22:89–104.CrossRefGoogle Scholar
  32. 32.
    Neoh CF, Snell G, Levvey B, Morrissey CO, Stewart K, Kong DCM. Antifungal prophylaxis in lung transplantation. Intl J Antimicrobial Agents. 2014;44:194–202.CrossRefGoogle Scholar
  33. 33.
    Geltner C, Lass-Florl C. Invasive pulmonary aspergillosis in organ transplants—focus on lung transplants. Resp Invest. 2016;54:76–84.CrossRefGoogle Scholar
  34. 34.
    Chambers DC, Sole A. Mold infections in cardiothoracic transplantation. In: Mooney ML, Hannan MM, Husain S, Kirklin JK, editors. Diagnosis and management of infectious diseases in cardiothoracic transplantation and mechanical circulatory support. Philadelphia: Elsevier; 2011. p. 195–209.Google Scholar
  35. 35.
    Elefanti A, Mouton JW, Verweij PE, Tsakris A, Zerva L, Meletiades J. Amphotericin B- and voriconazole-echinocandin combinations against Aspergillus species: effect of serum on inhibitory and fungicidal interactions. Antimicrob Agents Chemother. 2013;57:4656–63.CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Wu G, Vilchez RA, Eidelman B, Fung J, Kormos R, Kusne S. Cryptococcal meningitis: an analysis among 5521 consecutive organ transplant recipients. Transplant Infect Dis. 2022;4:183–8.CrossRefGoogle Scholar
  37. 37.
    Perfect JR, Dismukes WE, Dromer F, Goldman DL, Graybill JR, Hamill RJ, et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis. 2010;50:291–322.CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    Winthrop KL, Kubak BM, Pegues DA, Hufana C, Costamagna P, Desmond E, et al. Transmission of mycobacterium tuberculosis via lung transplantation. Am J Transplant. 2004;4:1529–33.CrossRefPubMedGoogle Scholar
  39. 39.
    Morris MI, Daly JS, Blumberg E, Kumar D, Sester M, Schluger N, et al. Diagnosis and management of tuberculosis in transplant donors: a donor-derived infections consensus conference report. Am J Transplant. 2012;12:2288–300.CrossRefPubMedGoogle Scholar
  40. 40.
    Mortenen E, Hellinger C, Keller C, Cowan LS, Shaw T, Hwang S, et al. Three cases of donor-derived pulmonary tuberculosis in lung transplant recipients and review of 12 previously reported cases: opportunities for early diagnosis and prevention. Transplant Infect Dis. 2014;16:67–75.CrossRefGoogle Scholar
  41. 41.
    Torre-Cisneros J, Doblas A, Aguado JM, San Juan R, Blanes M, Montejo M, et al. Tuberculosis after solid organ transplant: incidence, risk factors and clinical characteristics in the RESITRA (Spanish Network in Infection in Transplantation) cohort. Clin Infect Dis. 2009;48:1657–65.CrossRefPubMedGoogle Scholar
  42. 42.
    Morales P, Briones A, Torres JJ, Sole A, Perez D, Pastor A. Pulmonary tuberculosis in lung and heart-lung transplantation: fifteen years of experience in a single center in Spain. Transplant Proc. 2005;37:4050–5.CrossRefPubMedGoogle Scholar
  43. 43.
    Bravo C, Roldan J, Roman A, Degracia J, Majo J, Guerra J, et al. Tuberculosis in lung transplant recipients. Transplantation. 2005;79:59–64.CrossRefPubMedGoogle Scholar
  44. 44.
    Schulman LL, Scully B, McGregor CC, Austin JH. Pulmonary tuberculosis after lung transplantation. Chest. 1997;111:1459–62.CrossRefPubMedGoogle Scholar
  45. 45.
    Singh N, Paterson DL. Mycobacterium tuberculosis infection in solid-organ transplant recipients: impact and implications for management. Clin Infect Dis. 1998;27:1266–77.CrossRefPubMedGoogle Scholar
  46. 46.
    American Thoracic Society, CDC and Infectious Diseases Society of America. Treatment of tuberculosis. MMWR Morb Mortal Wkly Rep. 2003;52:1–77.Google Scholar
  47. 47.
    Morales P, Santos M, Hadjiliadis D, Aris RM. Mycobacterial infections in cardiothoracic transplantation. In: Mooney ML, Hannan MM, Husain S, Kirklin JK, editors. Diagnosis and management of infectious diseases in cardiothoracic transplantation and mechanical circulatory support. Philadelphia: Elsevier; 2011. p. 161–73.Google Scholar
  48. 48.
    Field SK, Cowie RL. Lung disease due to the more common nontuberculous mycobacteria. Chest. 2006;129:1653–72.CrossRefPubMedGoogle Scholar
  49. 49.
    Lobo LJ, Chang LC, Esther CR Jr, Gilligan PH, Tulu Z, Noone PG. Lung transplant outcomes in cystic fibrosis patients with preoperative mycobacterium abscessus respiratory infections. Clin Transpl. 2013;27:523–9.CrossRefGoogle Scholar

Copyright information

© The Author(s) 2018

Authors and Affiliations

  1. 1.Division of Pulmonary Sciences and Critical Care MedicineUniversity of ColoradoAuroraUSA

Personalised recommendations